0.6420
-0.0172
(-2.61%)
At close: April 9 at 4:00:00 PM EDT
0.6408
-0.00
(-0.19%)
After hours: April 9 at 7:40:07 PM EDT
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Gaston Paladini M.B.A. | Co-Founder, CEO & Director | -- | -- | 1981 |
| Mr. Henk Hoogenkamp Ph.D. | Co-Founder & Chief Product Officer | -- | -- | 1987 |
| Mr. Martin Salinas Ph.D. | Chief of Technology & Co-Founder | -- | -- | 1982 |
| Mr. Jose Lopez Lecube M.B.A. | CFO & Director | -- | -- | 1983 |
| Dr. Amit Dhingra Ph.D. | Chief Science Officer | -- | -- | 1971 |
| Florencia Bottero | Corporate Counsel & Secretary of the Board | -- | -- | -- |
| Ms. Catalina Jones B.A. | Chief of Staff & Sustainability | -- | -- | 1986 |
Moolec Science SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 52
Description
Moolec Science SA, a science-based food ingredient company, focuses on developing ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology. It develops textured soy proteins, safflower oil, meat replacement products, food ingredients, and nutritional supplements. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg, Luxembourg.
Corporate Governance
Moolec Science SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 10, 2025 at 12:30 PM UTC - April 17, 2025 at 12:30 PM UTC
Moolec Science SA Earnings Date
Recent Events
November 25, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Related Tickers
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.2930
-1.35%
FLUI.ST Fluicell AB (publ)
12.42
+7.25%
2GH.BE Merus NV
35.80
-0.56%
SIMRIS-B.ST Simris Group AB (PUBL)
0.0968
-0.41%
22Z.SG Zealand Pharma A/S
61.14
+8.98%
5KW.F SkinBioTherapeutics plc
0.2000
0.00%
DBP-B.ST Double Bond Pharmaceutical Int.
0.2710
-3.90%
HPHA.F Heidelberg Pharma AG
2.6200
+0.77%
DIABIO.ST Diagonal Bio AB (publ)
0.0145
0.00%
CHOSA.ST CHOSA Oncology AB
0.6500
-18.75%